Insulet (PODD) closed at $141.96 on Oct 19, 2026, up 0.6% on the day. The stock is up 1.0% over the past month, down 13.3% over three months, down 50.1% year to date and down 55.1% over the past year. It trades 60.0% below its 52-week high of $354.88 and 12.3% above its 52-week low of $126.40. The close sits above its 50-day moving average ($140.45) and below its 200-day moving average ($185.05).
NextPick tracks PODD in its Medical Devices basket alongside ABT, ISRG, MDT, SYK and BSX. As of Oct 19, 2026, the basket's money-flow score is 4 (neutral), and the basket is up 2.2% over five sessions. Over the past month PODD ranks 9th of 13 basket members by price change.
No — the Oct 19, 2026 close of $141.96 is 23.3% below the 200-day average of $185.05.
PODD closed 60.0% below its 52-week high of $354.88.
NextPick groups PODD with ABT, ISRG, MDT, SYK and BSX in its Medical Devices basket.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
